Loading
Inhibrx, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by VIKING GLOBAL INVESTORS LP, was filed 30 Aug 2023.
Inhibrx, Inc.: what insiders have been doing
Every trade that managers of Inhibrx, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. The past year has been quiet: not a single insider filing for Inhibrx, Inc. The previous disclosure was published on 3 June 2024.
Looking back to 2020, when coverage begins, insiders filed 8 purchases and 59 sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
93
Thresholds
n/a
Buy Volume
€55M
8 ops. · all time
Sell Volume
€26M
59 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
Revenue1.6M
Net income-214.9M-13408.9% margin
Last declaration on 3 June 2024
Declarations93 total
333,333 shares@ US$30.003.6% of flowCommon StockSEC:0000905148-24-001667:1
511,627 shares@ US$30.005.6% of flowCommon StockSEC:0000905148-24-001667:2
6,305,866 shares@ US$30.0081.4% of flowCommon StockSEC:0000905148-24-001667:0
25,000 shares@ US$30.000.8% of flowCommon StockSEC:0000950142-24-001499:1
1,735,553 shares@ US$30.0067.8% of flowCommon StockSEC:0000950142-24-001497:1
160,000 shares@ US$30.006.3% of flowCommon StockSEC:0000950142-24-001497:2
500,000 shares@ US$30.0015.9% of flowCommon StockSEC:0000950142-24-001500:1
59,462 shares@ US$30.001.9% of flowCommon StockSEC:0000950142-24-001500:2
3,224,301 shares@ US$30.0099.3% of flowCommon StockSEC:0000950142-24-001499:0
300,000 shares@ US$34.3066.1% of flowCommon StockSEC:0000950142-24-001497:0
598,257 shares@ US$30.00100.0% of flowCommon StockSEC:0000950142-24-001498:0
2,486,192 shares@ US$30.0097.8% of flowCommon StockSEC:0000950142-24-001500:0
511,627 shares@ US$19.354.3% of flowCommon StockSEC:0000905148-23-000804:0
Canonical exit: 26 Nov 2023 (T+90)
400 shares@ US$24.70750.0% of flowCommon StockSEC:0001739614-23-000016:1
39,600 shares@ US$24.20076.3% of flowCommon StockSEC:0001739614-23-000016:0
60 shares@ US$25.02080.0% of flowCommon StockSEC:0001739614-23-000014:0
14,608 shares@ US$25.07980.5% of flowCommon StockSEC:0001739614-23-000012:1
693 shares@ US$25.65670.0% of flowCommon StockSEC:0001739614-23-000012:2
10,120 shares@ US$25.40450.3% of flowCommon StockSEC:0001739614-23-000012:3
1,130 shares@ US$25.89470.0% of flowCommon StockSEC:0001739614-23-000012:4
13,449 shares@ US$24.29252.1% of flowCommon StockSEC:0001739614-23-000012:0
4,272 shares@ US$25.710.1% of flowCommon StockSEC:0001739614-23-000010:1
63 shares@ US$26.11270.0% of flowCommon StockSEC:0001739614-23-000010:2
21,665 shares@ US$25.35720.7% of flowCommon StockSEC:0001739614-23-000010:0
9,500 shares@ US$25.26310.2% of flowCommon StockSEC:0001739614-23-000008:0
25 of 93 declarations
About Inhibrx, Inc.
Inhibrx, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and other serious diseases. The company is listed on NASDAQ under the ticker INBX.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
